Top 5 Drug Type | Count |
---|---|
Small molecule drug | 18 |
Prophylactic vaccine | 2 |
Chemical drugs | 1 |
Synthetic peptide | 1 |
Proteolysis-targeting chimeras (PROTAC) | 1 |
Target |
Mechanism CB antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date25 Jun 2018 |
Target |
Mechanism TGF-β1 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism TGF-β1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Apr 2025 |
Sponsor / Collaborator |
Start Date15 Jan 2025 |
Sponsor / Collaborator |
Start Date10 Jan 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Mefunidone Hydrochloride ( TGF-β1 ) | Type 2 diabetes mellitus with established diabetic nephropathy More | Phase 2 |
JZTX-14 ( Nav1.5 ) | Triple Negative Breast Cancer More | Preclinical |
AN-329/43448068 ( HSPH1 x STAT3 ) | Pulmonary Arterial Hypertension More | Preclinical |
MPXV-5 ( TLR2 x TLR4 ) | Virus Diseases More | Preclinical |
MPXV-2 ( TLR2 x TLR4 ) | Virus Diseases More | Preclinical |